The approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...

Ali almost had his leg amputated due to the dangerous kicks from Inoki, his coach claimed in the years since the doomed fight ...

Winnie Byanyima says her organization has lost almost 50% of its funding, a gap that is undermining global efforts to combat ...

People who received a single fecal transplant via enema recovered slightly better from a Clostridioides difficile infection ...

University of Georgia researchers have successfully created a vaccine that protects and treats vaginal yeast infections in ...

A major win in the fight against HIV infections. The Food and Drug Administration approved a new twice-a-year shot to prevent ...

Agricultural researchers discovered how to essentially disarm Fusarium Head Blight, which causes over $1 billion in annual ...

Frailty strongly predicts worse RSV outcomes in older adults, highlighting the need for targeted care as aging populations ...

“Summer activities create the perfect storm for urinary tract infection (UTI) development,” Ross, a Winx Health Advisor, told ...

According to the latest data from the National Syndemic Diseases Control Council (NSDCC), the government had planned to ...

A major win in the fight against HIV infections as the Food and Drug Administration approved a new twice-a-year shot to ...

The injectable HIV prevention treatment Yetzugo, made by Gilead Sciences, has received FDA approval, offering a twice-yearly alternative to daily medications.